Insurance Hurdles Complicate Febrile Neutropenia Prevention in ES-SCLC

Platinum/etoposide regimens carry an intermediate risk of febrile neutropenia in extensive-stage small cell lung cancer (ES-SCLC), a category in which guidelines advise weighing primary granulocyte colony-stimulating factor (G-CSF) prophylaxis against patient risk factors.¹ Many patients present acutely ill and start treatment before those risks can be weighed, and requests for prophylaxis can meet insurance resistance. Trilaciclib (Cosela) is indicated before platinum/etoposide-containing regimens without a requirement for risk stratification,² but how it fits alongside G-CSF remains an open question for many practices.

In a live Community Case Forum event in Minneapolis, Minnesota, Mary Jo Fidler, MD, a professor of oncology at Rush University Medical Center in Chicago, reviewed the burden of chemotherapy-induced myelosuppression (CIM) and the evidence for trilaciclib, and moderated discussion of a case of first-line chemotherapy complicated by febrile neutropenia. Fidler noted that platinum/etoposide falls in the intermediate-risk category and that she has had difficulty getting primary G-CSF prophylaxis approved.

Register today to join a Case-Based Roundtable near you.

CASE SUMMARY

Patient Presentation

• 51-year-old woman
• Presented to the emergency room (ER) with cough, chest pain, and dyspnea

Past Medical History

• Thyroidectomy 5 years ago for papillary thyroid carcinoma (T2N0M0); on long-term levothyroxine; follow-up exams unremarkable; otherwise healthy

Smoking History

• 20 pack-year history

Physical Exam

• Thyroid deficiency; otherwise unremarkable

Performance Status (PS)

• ECOG PS of 1

Workup, Diagnosis, and Treatment

• Chest CT: 1.5 cm × 1 cm mass on the right pleural side, associated with pleural thickening and adhesion, and scattered satellite lesions; a minimal right pleural effusion; several mediastinal lymph nodes (largest measuring 1 cm × 1.8 cm; pericardial effusion); no evident anomalies in the left thoracic cavity
• Biopsy: Fine-needle aspiration confirms small cell lung cancer
• Imaging: No evidence of distant metastasis
• Diagnosis: ES-SCLC (right pleura, pericardium involvement); ECOG PS 1
• Treatment initiated: carboplatin/etoposide/atezolizumab (Tecentriq)

Clinical Update: Two Weeks After Cycle 1

• Symptoms: Chest pain and productive cough, with a fever of 100°–101°F over the past 24 hours
• Confirmed diagnosis: Labwork, imaging, and blood/sputum cultures confirm febrile neutropenia (absolute neutrophil count [ANC], 100) with sepsis in the presence of pneumonia

EVENT RECAP

Before the case was presented, 87.5% of 8 respondents said they typically take proactive measures to prevent CIM in patients receiving etoposide or topotecan for ES-SCLC, and none of the 8 had used trilaciclib before chemotherapy to do so. Fidler framed the stakes with patient-reported data from an online survey of 301 patients with breast, lung, or colorectal cancer, in which 36% reported that CIM affected their ability to complete daily tasks at home and 43% their ability to work.³

Participants described barriers that precede prophylaxis decisions. One oncologist said prior authorization for the immune checkpoint inhibitor can delay the start of treatment, and a fellow said that, because many patients are diagnosed during a hospital stay, teams often give chemotherapy alone through a peripheral IV and hold atezolizumab until the patient is an outpatient. The same oncologist also pointed to comorbidities, cytopenias, and the transportation burden of 3 consecutive treatment days.

Fidler noted that platinum/etoposide carries an intermediate risk of febrile neutropenia (10% to 20%), a category in which NCCN advises considering G-CSF based on patient risk factors, while it advises G-CSF for regimens with a risk greater than 20%.¹ "I don't use a lot of front-line [G-CSF]. I've had pushback from insurance authorizations," she said. She listed risk factors that can support a request, including a history of febrile neutropenia, age older than 65 years, frailty, low albumin, organ dysfunction, and comorbidities such as heart disease.⁴ Appeals cost time, and frailty assessment is hard to arrange. "I feel like nobody has time to go to the frailty clinic," she said.

Participants split on dose reduction. One fellow said they reduce doses when kidney function is abnormal or comorbidities and cytopenias are present, because treatment is palliative. Another oncologist favored giving more drug, reasoning that a regimen either works or does not, and said they prefer G-CSF to a first-cycle reduction. Fidler said she was trained with "a low threshold for dose reductions and modifications," but that she wonders about efficacy with that approach.

Trilaciclib, a transient CDK4/6 inhibitor, is indicated to decrease the incidence of CIM when given before platinum/etoposide- or topotecan-containing regimens for ES-SCLC.² It is dosed at 240 mg/m as a 30-minute infusion completed within 4 hours before chemotherapy on each day chemotherapy is given, and NCCN guidance lists it alongside G-CSF as a prophylactic option, with G-CSF permitted after cycle 1.^1,5

The phase 2 G1T28-05 study (NCT03041311) randomized patients with untreated ES-SCLC to trilaciclib or placebo before carboplatin, etoposide, and atezolizumab, with duration and occurrence of severe neutropenia as primary end points.⁶ Fidler noted that primary G-CSF prophylaxis was prohibited in cycle 1 across the studies. In a pooled analysis of randomized, placebo-controlled studies presented at the European Lung Cancer Congress (ELCC) 2026, trilaciclib (116 patients) vs placebo (114 patients) was associated with less severe neutropenia (3.4% vs 47.4%; P < .0001), less grade 3 or 4 anemia (14.7% vs 25.4%; P = .0269), less grade 3 or 4 thrombocytopenia (6.0% vs 27.2%; P = .0002), and less G-CSF use (29.3% vs 59.6%; P < .0001).⁷ Febrile neutropenia occurred in 2.6% vs 8.8% of patients, a difference Fidler said was not statistically significant.

Hospitalization for CIM or sepsis occurred in 4.1% vs 13.6% of patients with trilaciclib vs placebo (P = .0088) in the published pooled analysis of 3 phase 2 trials, including the pivotal study and 2 others (NCT02499770 and NCT02514447), while all-cause hospitalization did not differ significantly between arms.^7,8 In the pivotal study, dose reductions with trilaciclib vs placebo occurred in 1.9% vs 24.5% of patients for carboplatin and 5.8% vs 26.4% for etoposide, and cycle delays in 34.6% vs 58.5%, in secondary end points that were not statistically compared.⁹ Trilaciclib was associated with improvements in fatigue, physical well-being, and functional well-being in secondary patient-reported analyses.⁸ The label reports injection-site reactions, including phlebitis and thrombophlebitis, in 21% (56 of 272) of patients in clinical trials.² "There is a lot of burning with the trilaciclib, so we found it easier to give with a portacath," Fidler said.

When respondents ranked what matters most in considering trilaciclib, 4 of 8 ranked hospitalization incidence rate first, 3 ranked myelopreservation first, and 1 ranked patient outcomes first. Several participants said they did not know whether trilaciclib was built into their institutions' protocols, and one said formulary status was a concern. Another asked whether protecting stem cells in cycle 1 might reduce cumulative marrow toxicity over successive treatments. Fidler said real-world data, including from patients who receive G-CSF during lurbinectedin (Zepzelca) maintenance, would help answer that.

After the discussion, 87.5% of 8 respondents said they were likely to change their approach to febrile neutropenia prophylaxis for a similar patient receiving first-line platinum/etoposide and an immune checkpoint inhibitor, and 1 was unsure.

Participants treated hospitalization risk and access, not efficacy alone, as the practical test for trilaciclib, and most respondents said the case would change how they approach prophylaxis. Whether the advantages seen in the trials hold up in routine practice, and how formulary and insurance hurdles are handled for cycle 1, remained open.

Register today to join a Case-Based Roundtable near you.

DISCLOSURES: There were no relevant disclosures available at the time of publication.

REFERENCES

1. NCCN. Clinical Practice Guidelines in Oncology. Hematopoietic growth factors, version 1.2025. Accessed October 14, 2026. https://tinyurl.com/388ausmz

2. Cosela. Prescribing information. Pharmacosmos Therapeutics Inc; revised August 2025. Accessed October 14, 2026. https://tinyurl.com/568yw5k8

3. Epstein RS, Basu Roy UK, Aapro M, et al. Cancer patients' perspectives and experiences of chemotherapy-induced myelosuppression and its impact on daily life. Patient Prefer Adherence. 2021;15:453-465. doi:10.2147/PPA.S292462

4. NCCN. Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections, version 3.2024. Accessed October 14, 2026. https://tinyurl.com/5awv8hnh

5. NCCN. Clinical Practice Guidelines in Oncology. Small cell lung cancer, version 4.2025. Accessed October 14, 2026. https://tinyurl.com/y7emu2xt

6. Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer. 2021;148(10):2557-2570. doi:10.1002/ijc.33453

7. Weiss J, et al. Pooled analysis of trilaciclib in extensive-stage small cell lung cancer. Presented at: European Lung Cancer Congress (ELCC) 2026; Copenhagen, Denmark. Abstract 434P.

8. Weiss J, Goldschmidt J, Andric Z, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer. 2021;22(5):449-460. doi:10.1016/j.cllc.2021.03.010

9. Ferrarotto R, Anderson I, Medgyasszay B, et al. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials. Cancer Med. 2021;10(17):5748-5756. doi:10.1002/cam4.4089